Evidence map›Paper›PMID 38792047›Full record

ArticleMolecules (Basel, Switzerland)2024

Metabolism, Disposition, Excretion, and Potential Transporter Inhibition of 7-16, an Improving 5-HT

Zhengping Hu, Wenyan Wang, Huijie Yang, Fengjuan Zhao, Chunjie Sha, Wei Mi, Shuying Yin, Hongbo Wang, Jingwei Tian, Liang Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhengping HuMedicine and Pharmacy Research Center, Binzhou Medical University, Yantai 264003, China.
Wenyan WangSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
Huijie YangState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai 264003, China.
Fengjuan ZhaoState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai 264003, China.
Chunjie ShaState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai 264003, China.
Wei MiSchool of Public Health, Binzhou Medical University, Yantai 264003, China.
Shuying YinSchool of Public Health, Binzhou Medical University, Yantai 264003, China.
Hongbo WangSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
Jingwei TianSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
Liang YeSchool of Public Health, Binzhou Medical University, Yantai 264003, China.

Funding

"Taishan Industry Leading Talent Laureate" and the Major technological innovation project of Shandong Province PR China 2019JZZY011122
6 · The paper itself

Abstract

Compound 7-16 was designed and synthesized in our previous study and was identified as a more potential selective 5-HT

Indexed as

Parkinson DiseaseSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsAnimalsHumansMaleMethylationMicrosomes, LiverOxidation-ReductionPiperidinesPyridinesRatsPiperidinesPyridinesSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonistsexcretionmetabolic enzyme phenotypemetabolite identificationParkinson’s disease psychosisradioanalysisUPLC-Q Exactive HRMS

Identifiers

PMID38792047
PMCPMC11124362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.